What's Hot

View all perspectives
      RT @RichardPAConway: Patients with acute calcium pyrophosphate arthritis at ⬆️risk of cardiovascular events. Abstr#1

      Richard Conway RichardPAConway

      3 years 1 month ago
      Patients with acute calcium pyrophosphate arthritis at ⬆️risk of cardiovascular events. Abstr#1898 #ACR21 @RheumNow https://t.co/IOFYJnutHM
      RT @Janetbirdope: Why would higher active dose of #methotrexate with sc admin & more metabolites polyglutamates whic

      Janet Pope Janetbirdope

      3 years 1 month ago
      Why would higher active dose of #methotrexate with sc admin & more metabolites polyglutamates which can give side effects have LESS AEs? Never understood it! #ACR21 abst#1695 @RheumNow https://t.co/qrEKofX1cl
      RT @DrPetryna: Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PD

      Olga Petryna DrPetryna

      3 years 1 month ago
      Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PDE4 since 2018 guideline update: anti-IL17 compared to 2018 or earlier (30% vs 3.5% p< 0.001);anti-PDE4 (40% vs 11.5% p< 0.012). Meds SEs& prevention of joint damage important for pts
      RT @ericdeinmd: #ACR21 L16 - Breakthrough #COVID19 in rheum pts
      ⭐️Breakthrough ifn ~4%, compared to 3% wo rheum dise

      Eric Dein ericdeinmd

      3 years 1 month ago
      #ACR21 L16 - Breakthrough #COVID19 in rheum pts ⭐️Breakthrough ifn ~4%, compared to 3% wo rheum disease. Statistically signif ⬆️ risk in RA, gout, polymyositis, vasculitis, multiple rheum disease ⭐️bDMARD, multiple AIRD risks @Rheumnow https://t.co/cuM9LcEr4u https://t.co/Los2n7BoIn
      RT @doctorRBC: After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts
      ⭐️TNFi most common

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts ⭐️TNFi most common tx ⭐️28% pts not on any tx⭐️ #ACR21 @RheumNow Abs#1810 https://t.co/7Rmirfm3nK https://t.co/0Ui9pq5uyo
      RT @uptoTate: RHEKISS registry: SpA pts on bDMARDs at conception are NOT at inc. risk for adverse pregnancy outcomes. Di

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      RHEKISS registry: SpA pts on bDMARDs at conception are NOT at inc. risk for adverse pregnancy outcomes. Discontinuation of bDMARDs after conception is assoc'd w/ inc. dz activity during/after pregnancy & flare risk. Abs 1730 #ACR21 #RheumNow @RheumNow https://t.co/b2wI9GZios https://t.co/wsuvv3hF0v
      RT @Janetbirdope: The plague protection genetically can lead to Pyrin induced inflammasome activation. Theory of more FM

      Janet Pope Janetbirdope

      3 years 1 month ago

      The plague protection genetically can lead to Pyrin induced inflammasome activation. Theory of more FMF in Mediterranean / Turkey. So high protection gene in population Dan Kastner - a genetic detective 9T119 #ACR21 #ACRBest @RheumNow https://t.co/qzdc12fT0j

      RT @synovialjoints: In Phase 2 trial of Tildrakizumab in active PsA efficacy tended to be lower among patients with como

      Dr. Antoni Chan synovialjoints

      3 years 1 month ago
      In Phase 2 trial of Tildrakizumab in active PsA efficacy tended to be lower among patients with comorbid MetS, with improvements from baseline across efficacy measures generally larger in patients without MetS vs those with MetS @RheumNow #ACR21 Abst#1819 https://t.co/ATxaFz9X2O https://t.co/2iJMNmfUzg
      RT @RHEUMarampa: Post hoc analysis of pooled data from 19 clin trials on SEC &amp; CV risk &amp; systemic #inflammation

      sheila RHEUMarampa

      3 years 1 month ago
      Post hoc analysis of pooled data from 19 clin trials on SEC & CV risk & systemic #inflammation in PsO, PsA, AS 📌Traditional CV parameters remained stable on all SEC treated grps 📌SEC sig. ⬇hsCRP & NLR @RheumNow #ACR21 abs1835 https://t.co/iCaGFbXNXn
      RT @uptoTate: French study shows more than 75% of RA/SpA pregnancies resulted in a live-birth, BUT 50% of pts had at lea

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      French study shows more than 75% of RA/SpA pregnancies resulted in a live-birth, BUT 50% of pts had at least one unfavorable pregnancy outcome! However, miscarriage prevalence lower than in reported literature. Abs 1724 #ACR21 #RheumNow @RheumNow https://t.co/64PspIKPTu https://t.co/LyfHVARAgd
      RT @drdavidliew: IVIG can passively transfer donor Ab including 'clinically significant' e.g. HBcAb

      @OchsnerHospMed 123

      David Liew drdavidliew

      3 years 1 month ago
      IVIG can passively transfer donor Ab including 'clinically significant' e.g. HBcAb @OchsnerHospMed 123 pts HBcAb+ post-IVIG 37 had HBcAb- captured pre-IVIG of those, 22 received prob unnecessary antiviral Rx Be smart: pre-IVIG, anticipate - test HBV #ACR21 ABST1528 @RheumNow
      RT @doctorRBC: 2 year study shows low rates of radiographic progression in PsA pts on guselkumab
      #ACR21 @RheumNow Abs#1

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      2 year study shows low rates of radiographic progression in PsA pts on guselkumab #ACR21 @RheumNow Abs#1805 https://t.co/dobg3cEXXG https://t.co/m1P24qPAhy
      RT @_Castillo_Pedro: SERENA interim analysis on interruption of secukinumab in AS and PsA
      🔹&gt;=16 wks of Rx before i

      Pedro Castillo _Castillo_Pedro

      3 years 1 month ago
      SERENA interim analysis on interruption of secukinumab in AS and PsA 🔹>=16 wks of Rx before interruption of >= 3 mo. 🔹75-80% of pts reinitiated w/o loading phase 🔹AS: BASDAI, PGA stable 🔹PsA: SJC, TJC returned to Rx baseline https://t.co/3G6rVW8TPv #ACR21 Abst#1361 @RheumNow
      RT @uptoTate: Have you heard of pSpA? (Peripheral) pSpA: distinct clinical phenotype w/ intermediate features between pu

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Have you heard of pSpA? (Peripheral) pSpA: distinct clinical phenotype w/ intermediate features between pure PsA & pure axSpA but w/ a higher disease burden compared to both diseases, & lower use of b-DMARDs. Abs 1787 #ACR21 #ACRbest #RheumNow @RheumNow https://t.co/Wsysm7A0Y3 https://t.co/rwQ8ukBEDq
      RT @Janetbirdope: Genes for oral aphthous ulcers common in gen pop’n, Behcets and w auto inflammatory PFAPA - kids w f

      Janet Pope Janetbirdope

      3 years 1 month ago
      Genes for oral aphthous ulcers common in gen pop’n, Behcets and w auto inflammatory PFAPA - kids w fevers ⬆️IL12 Kastner practical gene stories @RheumNow #ACR21 9T119. Have a listen. Bench to bedside & back https://t.co/UkPzoYbBNb

      Podcasts

      • Bah Humbug Vitamin D (12.20.2024)
      • 54K Peptic Ulcers Annually (12.13.2024)
      • Don’t Buy Guitars (12.6.2024)

      Catch up on Conference Podcasts

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright 2024 All Rights Reserved.

      ×